Table 2.
Dog | CoPS | PFGE type | ST | Antibiogram | SCCmec | Time of occurrence (months) | ||||
---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||
0 | 1a | 6 | 8 | 12 | ||||||
1 | MSSP | A | Neg | |||||||
MRSP | F | 45 | OXA-ERY-CLI-GEN-DOX-SXT | NT | ||||||
2 | MSSP | A | Neg | |||||||
MRSP | F | 45 | OXA-ERY-CLI-GEN-DOX-SXT | NT | ||||||
3 | MSSP | B | Neg | |||||||
MRSP | F | 45 | OXA-ERY-CLI-GEN-DOX-SXT | NT | ||||||
4 | MSSP | B | Neg | |||||||
MRSP | C | 112 | OXA-ENR-ERY-CLI-GEN-DOX-SXT | A1 | ||||||
5 | MSSP | D | Neg | |||||||
MRSP | C | 112 | OXA-ENR-ERY-CLI-GEN-DOX-SXT | A1 | ||||||
6 | MSSP | E | Neg | |||||||
MRSP | H | 181 | OXA-ENR-ERY-CLI-GEN-DOX-SXT | V | ||||||
7 | MSSP | G | Neg | |||||||
MRSP | H | 181 | OXA-ENR-ERY-CLI-GEN-DOX-SXT | V | ||||||
8 | MSSP | I | Neg | |||||||
MRSP | C | 112 | OXA-ENR-ERY-CLI-GEN-DOX-SXT | A1 | ||||||
9 | MSSP | G | Neg | |||||||
MRSP | C | 112 | OXA-ENR-ERY-CLI-GEN-DOX-SXT | A1 | ||||||
10 | MSSP | J | Neg | |||||||
MRSP | F | 45 | OXA-ERY-CLI-GEN-DOX-SXT | NT |
CoPS — coagulase-positive staphyloccci; MSSP — methicillin-sensitive S. pseudintermedius; MRSP — methicillin-resistant S. pseudintermedius; PFGE — pulsed-field gel electrophoresis; ST — sequence type in multilocus sequence typing; NT — non-typable; Neg — negative.
1a: the samples were collected on the 7th day after onset of treatment. OXA — oxacillin; ERY — erythromycin; GEN — gentamicin; CLI — clindamycin; DOX — doxycycline; SXT — sulphamethoxazole; ENR — enrofloxacin.
A grey block indicates the presence of the clones at the time of sampling. All dogs had CoPS at each sampling time. Three samples were obtained from each dog, except for dog 9 samples were obtained.